Tumoral infiltrate after local treatment with interferon in squamous cell carcinoma.

Using monoclonal antibodies UCHL-1 (T lymphocytes), MT-1 (pan T) and L-26 (B lymphocytes) in the study of the tumoral infiltrate after local treatment with alpha interferon (Roferon) in patients with squamous cell carcinoma of the lower lip, it was observed that: the proportion of UCHL-1 positive cells was between 30% and 80%, the proportion of MT-1 positive cells was of 85% and that of the L-26 positive cells was of 30% of all the cells in the infiltrate. In the area in which after treatment with interferon the tumoral structures had disappeared, the proportion of T lymphocytes was smaller than in the areas in which the tumoral structures were still present. The therapeutic effect of interferon is due both to the direct effects on the tumoral cell and also to the indirect effects, namely the activation of the cytotoxic T lymphocytes and of other cells in the tumoral infiltrate.

Interleukin-2 (IL-2) in the treatment of malignant brain tumors (glioblastomas).

The present study is aimed to provide a new possible approach to the treatment of glioblastomas, in an effort to control the extremely severe evolution of these tumors. Thus, from May 28, 1991, we started the administration of IL-2 (produced at the "Victor Babeş" Institute, Bucharest) in 9 glioblastoma patients (operated on at the Neurosurgery department VII of the "G. Marinescu" Hospital, Bucharest) by repeated intraoperative and postoperative local injections.

Highly active effect of alpha interferon in blocking the cutaneous delayed hypersensitivity.

A group of 13 patients with contact dermatitis to various chemical compounds such as potassium dichromate, nickel sulphate, formaldehyde and balsam of Peru, was investigated by patch test and by the agreement between the history of disease and the patch test, the specific allergen involved in each special case could be demonstrated. Two-three days after the first patch test three normal skin areas were chosen. The first area was intradermally infiltrated with alpha-2a Interferon (IFN) (100,000 I.

Therapeutic effect of intralesional interferon (Roferon) in squamous cell carcinoma.

Recombinant alpha-2 interferon (IFN)--Roferon--100,000 IU/ml was intralesionally administered in 8 cases of squamous cell carcinoma (SCC) three times a week during 4-6 weeks in inoculations of 1 ml each. The therapeutic effect was scored as major--more than 60% reduction of the tumor size, moderate--30-60% reduction of the tumor mass and, nonreactive--less than 30% reduction of the tumor size. Three cases showed a major reduction, three showed a moderate reduction and two patients showed no reduction of the tumor volume.

Intralesional human leukocyte interferon treatment alone or associated with IL-2 in non-AIDS related Kaposi's sarcoma.

Patients with classical European Kaposi's sarcoma were treated by intra- and peritumoral injections of human alpha leukocyte interferon (IFN) (12 cases) or, alternatively, with IFN and naturally synthesized IL-2 (8 cases). All the patients were HIV negative with tumors which had been present for at least six months. In each patient, one tumor received 1 ml (50,000 IU) IFN alone or alternatively associated with 1 ml IL-2 twice a week for 4-6 weeks; another nodule situated 10-12 cm away was considered as a control and remained uninjected.

Human leukocyte interferon treatment associated with IL-2 in the non-AIDS related Kaposi's sarcoma.

Patients with classical European Kaposi's sarcoma have been treated by intra- and peritumoral injections of human alpha-leukocyte interferon (IFN) (12 cases) or alternatively with IFN and naturally synthetized IL-2 (8 cases). All the patients were HIV negative their tumour appearing at least six months before. In each patient one tumour received 1 ml (50,000 IU) IFM alone or associated, alternatively with 1 ml IL-2, twice a week during 4-6 weeks, whereas another nodule situated 8-10 cm apart was considered as control and remained uninjected.

[Immunomodulator effects of 2 kinds of interferon alpha on the in vitro synthesis of systemic and articular interleukin 1 in rheumatoid polyarthritis].

The authors have studied the synthesis of interleukin 1 by articular and circulating macrophages and the effect of two types of interferon alpha (IF) on this synthesis in 20 patients with untreated rheumatoid arthritis (RA). The articular and especially systemic interleukin levels in the RA patients are significantly higher than those of the test subjects. Interferon modifies in a very different way the production of interleukin 1 in the patients and in the test subjects.

Correlation of serum interferon with some clinical and humoral signs of systemic lupus erythematosus.

The serum level of total interferon (IFN) was measured in 15 male patients with systemic lupus erythematosus (SLE) in the active phase and in remission, before and during corticotherapy. The values found were correlated with the clinical and humoral signs of disease. The IFN titer was high in the active phase of disease and was correlated with fever, extension of skin rash, polyarthritis, myositis, autoimmune hemolysis, cardiac and cerebral involvement as well as with ESR, reacting protein C, CIC, ANF and the percentage of LE cells.

The role of tumor angiogenesis factor (TAF) in the tumor growth. Pathological aspects.

This work was carried out on control and immunosuppressed A2G mice inoculated with murine tumour cells (Ehrlich ascites) and human ones (KB cell line). The growth of the tumours was conditioned by the growth of the fibrovascular stromas as a response of the host organism to the TAF secretion. This process is a nonimmunological response, the differences between control and immunosuppressed mice being of no statistical significance.

S-phase detailed analysis in KB cells by bromdeoxyuridine labelling.

A method based on the sequential BrdU incorporation followed by differential spiralization of the chromosomes was used for analysis of S-phase in KB cells when Brdu was added to the cultures for 19, 24 and 26 hours before fixation. The S-phase was subdivided into three subphases, each recognisable by a specific incorporation pattern at metaphase: late-S (LS), middle-S (MS) and early -S (ES). Two other intermediary subphases, mid-early S (mES) and mid-late S (mLS) have also been distinguished but their accurate identification is generally difficult.

Intralesional human leukocyte interferon treatment in the non-AIDS related Kaposi's sarcoma.

Twelve patients with classical European Kaposi's sarcoma have been treated by intra- and peritumoral injections of human alpha leukocyte interferon (IFN)--Ginterferon ("V. Babeş Institute", Bucharest). All the patients were HIV negative their tumour appearing at least six months before.

The effect of human alpha leukocyte interferon (IFN) on the frequency of sister chromatid exchanges (SCE) in the KB cell line.

Concentrations of 50, 500 and 5,000 iu/ml of natural human alpha leukocyte interferon (IFN) were added into the culture medium of KB cells, 4 h after serial passage, in the presence of 5-bromo-desoxyuridine (Brdu) at 10 micrograms/ml. Similar cultures without IFN were set up as controls. After 72 h of incubation, the harlequin technique (differential staining of sister chromatids) was applied in order to discriminate among the metaphases of different generations and to appreciate the frequency of sister chromatid exchanges (SCE) in the second generation cells.

Interferon efficiency in the treatment of herpetic dermatites. II. Comparison between human leukocyte interferon (Ginterferon) and a recombinant interferon (Roferon).

The comparative efficiency of a recombinant interferon-Roferon (R-IFN) and a human, naturally synthetized interferon-Ginterferon (G-IFN), applied as ointments in the treatment of herpetic dermatites, was studied in a blind trial. It was found that R-IFN in doses of 20,000 IU/g has practically similar results as G-IFN in doses of 10,000 IU/g therefore half the dose of the former product. Thus both preparations reduced significantly the mean duration of a herpetic dermatitis attack and both proved more efficient on smaller lesions (less than 2 sq.

Interferon efficiency in the treatment of herpetic dermatites. I. A double-blind placebo controlled study.

The effect of an alpha human leukocyte interferon (IFN) locally applied as an ointment in herpetic dermatitis was investigated in a double blind trial. It was observed that IFN reduced significantly by 25-42% the mean healing period of attacks. This reduction was more important if the period till disappearance of vesicles was considered than if the period till complete epithelialization was taken into consideration.

An experimental model comparing the antineoplastic and the immunosuppressive effects of some cytostatics.

An experimental model evaluating comparatively the antineoplastic and the immunosuppressive effects of some cytostatics (cyclophosphamide and vinblastine) is described in the present paper. Different cytostatic doses were intraperitoneally administered in mice which were 24 hours later grafted with a suspension of human tumoral KB cells. The xenograft acceptance was macroscopically and microscopically recorded 21 days later.

Diagnostic value of serum interferon level in systemic lupus erythematosus.

In all the patients with systemic lupus erythematosus (SLE) tested in the active phase of the disease the serum interferon (IFN) level increases above the normal value (20 I.U./ml) reaching in some cases 80-160 I.

Anti-phospholipase C antibodies inhibit the lectin-induced proliferation of human lymphocytes.

A novel approach was used to assess the role of phosphoinositide hydrolysis in the mitogenic action of phytohemagglutinin (PHA) or concanavalin A (ConA). The treatment of human peripheral blood leukocytes (PBL) with monospecific antibodies against phospholipase C (PLC) produced a dose-dependent inhibition (up to 100%) of PHA (10 micrograms/ml) or ConA (25 micrograms/ml) proliferative effects. Thus, the activation of membrane-bound PLC is a sine-qua-non condition for lectin-induced proliferation of T lymphocytes.

Interferon level in human normal sera.

Interferon (IFN) level in the sera of normal humans was determined by their protective effect on a KB cell culture against the cytopathic effect (CPE) induced by vesicular stomatitis virus. The technique revealed all the three known types of IFN. In the investigated population 15 of 37 sera (40%) were found to protect against the CPE at 1/10 dilution, 11 of 37 (30%) still protect at 1/20 dilution, and 7 of 37 sera (19%) still protect at a dilution of 1/40.

The use of differential staining of sister chromatid to estimate the in vitro effect of human alpha interferon on cell division in normal and tumour cells.

Concentration of 10, 100 and 1000 I.U./ml of human leukocyte alpha interferon (IFN) were added into peripheral human blood (PBL) cultures and in KB cell cultures in the presence of 5-bromdeoxyuridine (BrdU) at 10 micrograms/ml.

Ginterferon (human leukocyte interferon) efficiency in the treatment of viral diseases. 1. Efficiency in viral keratoconjunctivitis.

Ginterferon is a human leukocyte interferon (IFN) produced in the "V. Babes" Institute by in vitro culture of leukocytes separated from neonatal cord blood. Ginterferon (50,000 IU/ml) was administered to 40 patients who suffered for at least two weeks of a hepatic keratoconjunctivitis resistant to treatment with conventional regimens of human immunoglobulins, Iduviran or topical antiinflammatory drugs.